Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
McKesson
Julphar
QuintilesIMS
Cipla
Cerilliant
Daiichi Sankyo
AstraZeneca

Generated: June 25, 2018

DrugPatentWatch Database Preview

ZOLMITRIPTAN - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for zolmitriptan and what is the scope of zolmitriptan freedom to operate?

Zolmitriptan
is the generic ingredient in three branded drugs marketed by Astrazeneca, Alembic Pharms Ltd, Apotex Inc, Glenmark Generics, Jubilant Generics, Macleods Pharms Ltd, Zydus Pharms Usa Inc, Ajanta Pharma Ltd, Appco Pharma Llc, Aurobindo Pharma Ltd, Invagen Pharms, Mylan Pharms Inc, Pld Acquisitions Llc, Sun Pharma Global, Teva Pharms Usa, and IPR, and is included in twenty-two NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Zolmitriptan has forty-two patent family members in twenty-eight countries.

There are twenty drug master file entries for zolmitriptan. Twenty-one suppliers are listed for this compound.
Synonyms for ZOLMITRIPTAN
(4S)-4-((3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-5-YL)METHYL)-2-OXAZOLIDINONE
(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
(4S)-4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
(4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]oxazolidin-2-one
(S) -N,N-Dimethyl-2- [5- (2-oxo-1,3-oxazolidin-4-ylmethyl) -1H -indol-3-yl]ethylamine
(S)-4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
(S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one
(S)-4-((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)-2-oxazolidinone
(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
(S)-4-(3-[2-(DIMETHYLAMINO)ETHYL]-5-INDOLYLMETHYL)OXAZOLIDIN-2-ONE
(S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone
(S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one
(S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H -indol-3-yl]ethylamine
(S)-N,N-Dimethyl-2-[5-(2-oxo-1,3-oxazolidin-4-ylmethyl)-1H-indol-3-yl]ethylamine
139264-17-8
2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)-
2FS66TH3YW
311C90
4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone
4-[[3-(2-dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one
64Z178
A-2479
AB00698244_06
AB00698244-05
AB07628
AB2000194
AC1L1U2E
ACT04392
AK-47834
AKOS015850706
AN-5272
AscoTop
AscoTop (TN)
AscoTopand
AT-3239
B2261
BC206232
BDBM50033383
BIDD:GT0040
BW-311C90
C07218
C16H21N3O2
CAS-139264-17-8
CCG-38993
CHEBI:10124
CHEMBL1185
CPD000449310
CS-2179
D00415
D0NG7O
DB00315
DSSTox_CID_25933
DSSTox_GSID_45933
DSSTox_RID_81232
DTXSID8045933
Flezol
FT-0631159
GTPL60
HMS1922B04
HMS2052K17
HMS2093O14
HMS2235I22
HY-B0229
J-007257
J10141
KB-62428
KS-00000HAJ
KS-5072
LS-100559
MFCD00871503
MLS000758208
MLS001424172
MolPort-003-666-626
NC00382
NCGC00095155-01
NCGC00263884-02
NCGC00263884-03
NSC-760383
NSC760383
Pharmakon1600-01505281
Rapimelt
s1649
SAM001246841
SAM001247064
SBI-0206762.P001
SC-17326
SCHEMBL33336
SMR000449310
SPBio_000656
SPECTRUM1505281
Spectrum2_000728
SR-05000001693
SR-05000001693-1
ST2407794
Tox21_111455
Tox21_111455_1
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
UNII-2FS66TH3YW
ZINC15515
zipton
ZMT
Zolmitriptan (JAN/USAN/INN)
Zolmitriptan (Zomig)
Zolmitriptan [USAN]
Zolmitriptan RapidFilm
Zolmitriptan, >=98% (HPLC)
Zolmitriptan, United States Pharmacopeia (USP) Reference Standard
zolmitriptane
zolmitriptanum
Zomig
Zomig (TN)
Zomig Nasal Spray
Zomig ZMT
Zomig-ZMT
Zomig, Zomigon, AscoTopand, Zomigoro, Zolmitriptan
Zomig;Zomigon;AscoTopand;Zomigoro
Zomigon
Zomigon (TN)
Zomigoro
Zomigoro (TN)
zominat

US Patents and Regulatory Information for ZOLMITRIPTAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipr ZOMIG zolmitriptan TABLET;ORAL 020768-001 Nov 25, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Macleods Pharms Ltd ZOLMITRIPTAN zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 204336-002 Oct 22, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Pharms Inc ZOLMITRIPTAN zolmitriptan TABLET;ORAL 203186-002 May 14, 2013 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc ZOLMITRIPTAN zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 202890-002 May 15, 2013 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ZOLMITRIPTAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-001 Feb 13, 2001 ➤ Sign Up ➤ Sign Up
Ipr ZOMIG zolmitriptan TABLET;ORAL 020768-001 Nov 25, 1997 ➤ Sign Up ➤ Sign Up
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-004 Sep 30, 2003 ➤ Sign Up ➤ Sign Up
Ipr ZOMIG zolmitriptan TABLET;ORAL 020768-001 Nov 25, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ZOLMITRIPTAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/089 United Kingdom ➤ Sign Up PRODUCT NAME: ZOLMITRIPTAN AND OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 12619/0116 19970307
80001 Netherlands ➤ Sign Up PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 21079, RVG 21080 19970925; FIRST REGISTRATION: GB PL 12619/0116 19970307
/1997 Austria ➤ Sign Up PRODUCT NAME: ZOLMITRIPTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ZULAESSIGEN SALZES; NAT. REGISTRATION NO/DATE: 1-22068, 1-22069 19970819; FIRST REGISTRATION: GB 12619/0116, 12619/0117 19970307
0048 Netherlands ➤ Sign Up PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Army
Express Scripts
Cipla
McKesson
Covington
Moodys
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.